Alto Neuroscience Stock

altoneuroscience.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $151.37MM

Alto Neurosciences is a biopharma company that uses biomarkers of the brain to understand prospective drug therapies for psychiatric care of patients. Alto Neurosciences specializes in precision medicine, and has established a pipeline of treatments for various mental health conditions such as post-traumatic stress disorders (PTSD) and depression.

Register To Buy and Sell Shares

For more details on financing and valuation for Alto Neuroscience, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Alto Neuroscience’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Alto Neuroscience.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Alto Neuroscience investors also invested in these private companies

Vine Ventures
Windham Venture Partners
Sobrato Capital
Korify Capitals
Bioverge Ventures
K2 HealthVentures
InVivium Capital
Lightswitch Capital
Catena Capital


Management Team

Amit Etkin Ph.D
Co-Founder & Chief Executive Officer
Nick Smith
Chief Financial Officer & Chief Business Officer
Dan Segal
Co-Founder, Chief Strategy Officer & Chief Operating Officer
Mikael Eliasson MD
Chief Operating Officer
Erin McQuade JD
Chief Administrative Officer & General Counsel
Jessica Powell
Chief Development Officer
Wei Wu Ph.D
Co-Founder & Chief Data Science Officer
Adam Savitz Ph.D
Chief Medical Officer

Board Members

Aaron Weaver
Apeiron Investment Group
Chris Dimitropoulos
Alpha Wave Global
Christopher Cox JD
Lightswitch Capital
Michael Liang Ph.D
InVivium Capital

News Highlights

Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing
Alto Neuroscience, Inc. today announced an oversubscribed $45 million Series C financing. The round was led by InVivium Capital, with participation from additional new investors Franklin Templeton, Point72, Eli Lilly and Company, and Alexandria Venture Investments. Existing investors Alpha Wave Ventures, Lightswitch Capital, partners of Alkeon Capital, WhatIf Ventures, and Windham Venture Partners also participated in the financing.
Alto Neuroscience Announces $35 Million Series B Financing
Alto Neuroscience today announced the closing of a $35 million Series B financing led by Lightswitch Capital and partners of Alkeon Capital, with participation from other new investors including Sobrato Capital, Novartis Pharma AG, Valor Equity Partners, Korify Capital, Vine Ventures, and Gaingels.
Updated on: Apr 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.